Castle Biosciences Inc (NASDAQ:CSTL) Chief Financial Officer Frank Stokes executed several equity transactions on March 3 and March 4, 2026, combining open-market sales, option exercises and restricted stock unit vesting.
On March 3, Stokes sold a total of 7,000 shares of Castle Biosciences common stock in two separate trades. The larger of the two sales comprised 5,300 shares at a weighted average price of $27.32, with execution prices spanning $26.70 to $27.67. The smaller block involved 1,700 shares sold at a weighted average price of $27.81, with prices in the $27.72 to $27.97 range. Combined, those March 3 transactions generated approximately $192,073.
In closely related activity, on March 3 and March 4 Stokes sold an additional 14,343 shares of common stock to satisfy tax obligations, a disposition valued at $401,875.
Also on March 4, Stokes exercised stock options to acquire 27,946 shares of Castle Biosciences common stock and received 48,367 Restricted Stock Units (RSUs). The timing of the exercises and RSU receipt followed the sales and tax-related dispositions.
Market context
The insider transactions came amid recent share price movement. According to InvestingPro data cited alongside the transactions, Castle Biosciences stock has declined 5.6% over the prior week even as the shares trade up 35.6% over the past 12 months. InvestingPro analysis referenced by the company notes that the stock appears to trade below its Fair Value, categorizing it among undervalued opportunities - a valuation view available through InvestingPro research tools.
Quarterly results and analyst response
Castle Biosciences reported fourth-quarter 2025 results that exceeded expectations on both the top and bottom lines. The company posted a diluted loss per share of $0.08 for the period, notably better than the consensus forecasted loss of $0.32, representing a 75% positive surprise versus expectations. Revenue for the quarter totaled $87 million, beating the anticipated $77.09 million by 12.86%. Management attributed the revenue improvement to higher year-over-year volumes across most of its tests, consistent with the company's earlier preannouncement.
Following those results, Canaccord Genuity reiterated a Buy rating on Castle Biosciences and maintained a $50 price target. The firm based its constructive stance on the company outperforming both its own forecasts and FactSet consensus estimates.
What the filings show
The sequence of disclosures captures a mix of regular executive actions: open-market sales on March 3, tax-covering dispositions on March 3 and 4, and option exercises plus RSU awards on March 4. The filings document precise share counts and dollar values but do not provide additional commentary on the motivations beyond the tax-related sale notation for the 14,343-share disposition.
Investors seeking the full InvestingPro research coverage and the Pro Research Report referenced in filings can consult InvestingPro for in-depth valuation and comparative analysis, which the data provider indicates covers CSTL and more than 1,400 U.S. equities.